EMA Chief Says Brexit Has Impaired Ability To Support R&D
The reduction in the European Medicines Agency’s activities since the UK voted to leave the EU nearly three years has impaired the regulator's ability to keep up with scientific and regulatory developments, and it is facing more staff losses as a result of its relocation to the Netherlands. However, the agency says it has managed to safeguard its core activities relating to the evaluation and supervision of medicines, and that the EU regulatory network should be able to adapt to Brexit-related changes without jeopardizing the quality of its work.
You may also be interested in...
EMA Gets Keys To New HQ And Restarts Some Stalled Activities
The European Medicines Agency has taken possession of its new HQ in Amsterdam and has hired 77 new staff members to make up for the severe staff losses it has witnessed on account of Brexit.
Search For Rasi's Successor At EMA Extended
The new head of the European Medicines Agency will need some solid leadership skills to steer the agency through the challenges of Brexit and to engage on issues including quality of innovation, affordability of medicines and improving patient access.
MHRA Chief Underlines Support For UK Innovation In Any Brexit Scenario
MHRA chief executive emphasizes at a conference in Mumbai the agency's continued commitment to supporting innovation in the UK, regardless of the outcome of Brexit.